Study of Safety and Efficacy of Multiple VAY736 Doses in Patients With Moderate to Severe Primary Sjogren's Syndrome (pSS)
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs VAY 736 (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 13 Nov 2017 Planned End Date changed from 13 Nov 2019 to 16 Dec 2019.
- 13 Jul 2017 Status changed from not yet recruiting to recruiting.
- 11 May 2017 Planned End Date changed from 1 Sep 2019 to 13 Nov 2019.